The Searle Company Limited has announced a series of strategic initiatives aimed at strengthening its position in Pakistan’s growing biopharmaceutical sector. The developments, disclosed to the Pakistan Stock Exchange, reflect the company’s commitment to optimizing its product portfolio, enhancing operational efficiency, and expanding its presence in the biologics market.
As part of the restructuring effort, Searle’s indirect subsidiary, Nextar Pharma (Private) Limited, is in the process of being renamed Searle Biopharma (Private) Limited. The proposed name change has already been reserved with the Securities and Exchange Commission of Pakistan (SECP) and is intended to better align the subsidiary’s identity with its core business activities.
In a significant strategic move, the Board of Directors has approved the proposed transfer of selected biological and associated products from The Searle Company Limited to its indirect subsidiary. The transfer is expected to include relevant trademarks, product registrations, authorizations, and technical information associated with the biologics portfolio. This initiative is designed to consolidate biologics-related operations within a dedicated entity, allowing for greater specialization and operational efficiency.
To support the expansion of the biologics business, the Board has also resolved to recommend shareholder approval for a proposed investment of up to PKR 4 billion in the share capital of Nextar, through Searle Biosciences (Private) Limited, a wholly owned subsidiary of the company. The investment will facilitate the acquisition and development of the biologics portfolio and support future growth opportunities within the segment.
The proposed transactions remain subject to the necessary regulatory and shareholder approvals, including compliance with the applicable provisions of the Companies Act, 2017. The company has indicated that further details regarding the arrangements and shareholder meeting will be communicated in due course.
These strategic initiatives highlight Searle’s long-term vision of strengthening its healthcare portfolio, enhancing value creation for shareholders, and positioning itself as a leading player in Pakistan’s evolving biopharmaceutical industry.
